Autonomous AI Assisted Salt Selection for Stability and Performance

自主人工智能辅助盐选择以提高稳定性和性能

• 批准号: 2890482
• 金额: --
• 依托单位: University of Strathclyde
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2890482
• 关键词: Autonomous; AI; Assisted; Salt; Selection

This project will deliver an AI-driven decision-making system for predictive salt selection for pharmaceutical APIs. In addition, the project will explore the pharmaceutical materials science (structure-process-property-performance) relationships that inform our Crystallisation Classification System development (CCS). The work will build our industry demand led programme aligned to CMAC's Lab of the Future vision for to accelerate product and process design by incorporating off-line measurement, collaborative robotics, analysis and decisions into an autonomous smart development platform or DataFactory.BackgroundIn the UK the pharmaceutical industry in 2018 was responsible for a £49bn turnover of goods, with a gross revenue from retail sales of £5bn (Office for National Statistics (UK), 2018). Also, in 2018, it was identified that artificial intelligence (AI) applications could add an additional £630bn to the UK economy by 2035 (Deep Knowledge Analytics, 2018, AI in the UK). This has been stimulated by advances in AI in a wide range of sectors, e.g. materials discovery (Schmidt, et al., 2019, Nature Computational Materials), and has provoked responses in government strategy, e.g. Scotland's AI Strategy Open Call. Most recently the emergence of Industry 5.0 principles that seek to build in human centricity, resilience and sustainability to manufacturing: these goals are especially important in the medicines manufacturing area.The pharmaceutical industry is facing increasing demands to deliver a higher variety of products more quickly, economically and sustainably. To achieve this, the sector seeks to make better use of cyber-physical production systems with a specific focus on digital twins and how they can be used to simulate manufacturing processes during development and hence reduce material requirements to validate processes before operation (Kemppainen, 2017, European Pharmaceutical Review). As a method of purification and forming the pharmaceutically relevant polymorph (Lee, 2014, Asian Journal of Pharmaceutical Sciences; Kesisoglou, et al., 2008, The AAPS Journal), crystallisation of the active pharmaceutical ingredient (API) is a key step in pharmaceutical manufacturing that impacts downstream processes. Determining an industrial-relevant approach for API crystallisation can be resource-intensive as a candidate crystallisation process is constrained by and assessed against industrial relevant solubilities, downstream processing practicalities, and regulator-determined Critical Quality Attributes (CQA) of the API (Chen, et al.,2011, Crystal growth & design; Brown et al., 2018, Molecular Systems Design & Engineering). Critically as ca. 40% of marketed APIs are practically insoluble, salt (and/or co-crystal) selection is a key step in the API form selection process which can provide up to 1000 fold increase in aqueous solubility. Yet suitable counterion selection remains largely trial and error and the resultant form stability and performance (disproportionation) can be impacted by salt crystal structure; impact of excipients in the formulated product on microenvironmental pH and disproportionation; buffer capacity of salts and excipients. The existing DataFactory at CMAC funded via EPSRC Hub and UK RPIF Net Zero Pilot support, uses high throughput small-scale crystallisation experiments coupled with machine learning to reduce the time and material costs associated with exploring the crystallisation design space for APIs. In addition the project is developing a unique Crystallisation Parameter Database that will fuel further basic and applied research moving towards the development of a Crystallisation Classification System (CCS) that will autonomously identifies industrially-relevant experimental conditions for any given API to achieve required performance, stability or manufacturability objectives.

该项目将提供一个人工智能驱动的决策系统，用于药物API的预测性盐选择。此外，该项目将探索药物材料科学（结构-工艺-性质-性能）的关系，为我们的结晶分类系统开发（CCS）提供信息。这项工作将建立我们的行业需求导向计划，与CMAC未来实验室的愿景保持一致，通过将离线测量，协作机器人，分析和决策纳入自主智能开发平台或DataFactory中，加速产品和工艺设计。背景在英国，2018年制药行业的商品销售额为490亿英镑，零售总收入为50亿英镑（英国国家统计局，2018年）。此外，在2018年，据确定，到2035年，人工智能（AI）应用可以为英国经济增加6300亿英镑（Deep Knowledge Analytics，2018，AI in the UK）。人工智能在广泛领域的进步刺激了这一点，例如材料发现（施密特等人，2019年，自然计算材料），并引起了政府战略的回应，例如苏格兰的人工智能战略公开呼吁。最近，工业5.0原则的出现，旨在建立以人为本，弹性和可持续性的制造：这些目标在药品制造领域尤为重要。制药行业正面临着越来越多的需求，以更快，更经济和可持续的方式提供更多种类的产品。为了实现这一目标，该行业寻求更好地利用网络物理生产系统，特别关注数字孪生，以及如何在开发过程中使用它们来模拟制造过程，从而减少材料要求，以便在操作前验证过程（Kemppainen，2017，欧洲制药评论）。作为纯化和形成药学上相关的多晶型物的方法（Lee，2014，Asian Journal of Pharmaceutical Sciences; Kesisoglou，et al.，2008，The AAPS Journal），活性药物成分（API）的结晶是药物制造中影响下游工艺的关键步骤。确定用于API结晶的工业相关方法可能是资源密集型的，因为候选结晶过程受到工业相关溶解度、下游加工实用性和监管机构确定的API的关键质量属性（CQA）的约束并针对其进行评估（Chen等人，2011，晶体生长与设计; Brown等人，2018年，分子系统设计与工程）。关键是CA。40%的市售API几乎不溶，盐（和/或共晶）选择是API形式选择过程中的关键步骤，其可提供高达1000倍的水溶性增加。然而，合适的辅料选择仍然主要是试验和错误，并且所得形式的稳定性和性能（纯化）可能受到以下因素的影响：盐晶体结构;配制产品中的辅料对微环境pH和纯化的影响;盐和辅料的缓冲能力。CMAC现有的DataFactory由EPSRC Hub和UK RPIF Net Zero Pilot支持资助，使用高通量小规模结晶实验与机器学习相结合，以减少与探索API结晶设计空间相关的时间和材料成本。此外，该项目正在开发一个独特的结晶参数数据库，这将推动进一步的基础和应用研究，朝着开发结晶分类系统（CCS）的方向发展，该系统将自动识别任何给定API的工业相关实验条件，以实现所需的性能，稳定性或可制造性目标。